Vascular Flow Technologies

Executive Summary

Vascular Flow Technologies is a UK-based medical device company specializing in cardiovascular applications through its proprietary Spiral Laminar Flow (SLF™) technology. The company aims to integrate SLF into vascular implants to restore natural blood flow patterns, thereby reducing complications such as thrombosis and intimal hyperplasia, and extending device longevity. In addition to developing its own products, VFT offers a full range of services from pre-clinical development to contract manufacturing under ISO 13485 certification, positioning itself as both an innovator and a partner to other medical device firms. Despite being in the pre-clinical stage, the company has built a strong IP portfolio around SLF and is advancing toward human studies. The global vascular graft and stent market faces persistent challenges with patency rates, especially in small-diameter applications. VFT's SLF technology addresses this unmet need by mimicking physiological hemodynamics, potentially improving outcomes for patients requiring bypass grafts, arteriovenous access, or endovascular stents. If successfully translated, SLF could become a standard of care, representing a significant value proposition. The company's focus on a validated technology platform and its dual strategy of product development and service provision mitigate risk while offering multiple paths to revenue. With increasing interest in advanced vascular solutions, VFT is well-positioned to attract partnerships and funding as it progresses toward clinical milestones.

Upcoming Catalysts (preview)

• 2026FDA Breakthrough Device Designation for SLF technology60% success
• Q1 2027Initiation of first-in-human clinical trial of SLF-enhanced vascular graft65% success
• 2026Strategic collaboration or licensing agreement with a major cardiovascular company45% success